Sex differences in the subjective tolerability of antipsychotic drugs

Journal of Clinical Psychopharmacology

Volumn 25, Issue 6, 2005, Pages 521-526

  Barbui, Corrado ^a   Nosè, Michela ^a   Bindman, Jonathan ^b   Schene, Aart ^c   Becker, Thomas ^d,e   Mazzi, Maria A ^a   Kikkert, Martijn ^c   Camara, Jayne ^b   Born, Anja ^d   Tansella, Michele ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d UNIVERSITY OF LEIPZIG   (Germany)

^e UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ANTICHOLINERGIC EFFECT; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DREAMING; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; EMOTIONAL DISORDER; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; GEOGRAPHY; GERMANY; HEART PALPITATION; HUMAN; HYPERSALIVATION; INVOLUNTARY MOVEMENT; ITALY; LIBIDO; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MENTAL CONCENTRATION; MENTAL DISEASE; MENTAL HEALTH SERVICE; MOTOR DYSFUNCTION; MUSCLE SPASM; MUSCLE STIFFNESS; NETHERLANDS; PHOTOSENSITIVITY; PRIORITY JOURNAL; PRURITUS; RATING SCALE; RESTLESSNESS; SCHIZOPHRENIA; SEX DIFFERENCE; SEXUAL DYSFUNCTION; SHAKINESS; SIDE EFFECT; SKIN MANIFESTATION; SLEEP DISORDER; SOMNOLENCE; SWEATING; TENSION; THORAX DISEASE; UNITED KINGDOM; VISUAL IMPAIRMENT; WEIGHT GAIN; XEROSTOMIA;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEALTH SURVEYS; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; QUALITY OF LIFE; SCHIZOPHRENIA; SEX FACTORS;

EID: 27944466131     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000185423.15891.02     Document Type: Article

References (27)

1. Naber D. Subjective effects of antipsychotic treatment. Acta Psychiatr Scand. February 2005;111:81-83.
2. Lambert M, Naber D. Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life. CNS Drugs. 2004;18(suppl 2):5-17.
3. Naber D, Karow A. Good tolerability equals good results: the patient's perspective. Eur Neuropsychopharmacol. October 2001;11(suppl 4):S391-S396.
4. Kasper S. First-episode schizophrenia: the importance of early intervention and subjective tolerability. J Clin Psychiatry. 1999;60(suppl 23):5-9.
5. Ritsner M, Gibel A, Perelroyzen G, et al. Quality of life outcomes of risperidone, olanzapine, and typical antipsychotic s among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. J Clin Psychopharmacol. December 2004;24:582-591.
6. Awad AG, Voruganti LN. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs. 2004;18:877-893.
7. Awad AG, Voruganti LN. New antipsychotics, compliance, quality of life, and subjective tolerability - are patients better off? Can J Psychiatry. May 2004;49:297-302.
8. Casey DE. Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr Res. March 1991;4:109-120.
9. Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry. September 1993;50:723-733.
10. Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull. 1992;18:701-715.
11. Seeman MV. Gender differences in the prescribing of antipsychotic drugs. Am J Psychiatry. August 2004;161:1324-1333.
12. Wing JK, Babor T, Brugha T, et al. SCAN. Schedules for Clinical Assessment in Neuropsychiatry. Arch Gen Psychiatry. June 1990;47:589-593.
13. Ruggeri M, Gater R, Bisoffi G, et al. Determinants of subjective quality of life in patients attending community-based mental health services. The South-Verona Outcome Project 5. Acta Psychiatr Scand. February 2002;105:131-140.
14. Jones SH, Thornicroft G, Coffey M, et al. A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry. May 1995;166:654-659.
15. Dingemans PM, Linszen DH, Lenior ME, et al. Component structure of the expanded Brief Psychiatric Rating Scale (BPRS-E). Psychopharmacology (Berlin). December 1995;122:263-267.
16. Ruggeri M, Koeter M, Schene A, et al. Factor solution of the BPRS-expanded version in schizophrenic outpatients living in five European countries. Schizophr Res. 2005;1(75):107-117.
17. Day JC, Wood G, Dewey M, et al. A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. Br J Psychiatry. May 1995;166:650-653.
18. Morrison P, Gaskill D, Meehan T, et al. The use of the Liverpool University Neuroleptic Side-Effect Rating Scale (LUNSERS) in clinical practice. Aust N Z J Ment Health Nurs. December 2000;9:166-176.
19. WHO Collaborating Centre for Drug Statistic Methodology. Guidelines for ATC classification and DDD assignment. Oslo, Norway: WHO; 2003.
20. Efron B, Tibshirani R. Bootstrap methods of standard errors confidence intervals and other measures of statistical accuracy. Stat Sci. 1986;1:54-77.
21. Morrison P, Meehan T, Gaskill D, et al. Enhancing case managers' skills in the assessment and management of antipsychotic medication side-effects. Aust N Z J Psychiatry. October 2000;34:814-821.
22. Voruganti L, Cortese L, Oyewumi L, et al. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res. June 2000;16(43):135-145.
23. Watanabe A, Shibata I, Kato T. Differences of satisfaction with medication between patients with schizophrenia treated with typical antipsychotics and atypical antipsychotics. Psychiatry Clin Neurosci. June 2004;58:268-273.
24. Castle D, Morgan V, Jablensky A. Antipsychotic use in Australia: the patients' perspective. Aust N Z J Psychiatry. October 2002;36:633-641.
25. Day JC, Kinderman P, Bentall R. A comparison of patients' and prescribers' beliefs about neuroleptic side-effects: prevalence, distress and causation. Acta Psychiatr Scand. January 1998;97:93-97.
26. Guyatt G, Cook D, Haynes B. Evidence based medicine has come a long way. BMJ. October 2004;329(7473):990-991.
27. Haynes B, Haines A. Barriers and bridges to evidence based clinical practice. BMJ. 1998;25(317):273-276.